96 related articles for article (PubMed ID: 32561130)
1. Imaging and biodistribution of radiolabeled SP90 peptide in BT-483 tumor bearing mice.
Lo WL; Liang CH; Chen LC; Lee SY; Lo SN; Chen MW; Lu RM; Liu IJ; Wu HC; Chang CH
Appl Radiat Isot; 2020 Jul; 161():109162. PubMed ID: 32561130
[TBL] [Abstract][Full Text] [Related]
2. Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice.
Lo WL; Lo SW; Chen SJ; Chen MW; Huang YR; Chen LC; Chang CH; Li MH
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34064291
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
[TBL] [Abstract][Full Text] [Related]
4. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
Dijkgraaf I; Kruijtzer JA; Frielink C; Corstens FH; Oyen WJ; Liskamp RM; Boerman OC
Int J Cancer; 2007 Feb; 120(3):605-10. PubMed ID: 17096340
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive Classification of Human Triple Negative Breast Cancer by PET Imaging with GRP78-Targeted Molecular Probe [
Zhao H; Meng H; Wen J; Wang C; Liu J; Huang G
Mol Imaging Biol; 2020 Jun; 22(3):772-779. PubMed ID: 31452065
[TBL] [Abstract][Full Text] [Related]
6. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
[TBL] [Abstract][Full Text] [Related]
7. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
9. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the RGD Motif-Containing α
Roesch S; Lindner T; Sauter M; Loktev A; Flechsig P; Müller M; Mier W; Warta R; Dyckhoff G; Herold-Mende C; Haberkorn U; Altmann A
J Nucl Med; 2018 Nov; 59(11):1679-1685. PubMed ID: 29674419
[TBL] [Abstract][Full Text] [Related]
11.
Ogawa K; Echigo H; Mishiro K; Hirata S; Washiyama K; Kitamura Y; Takahashi K; Shiba K; Kinuya S
Mol Pharm; 2021 Sep; 18(9):3553-3562. PubMed ID: 34403257
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model.
Froidevaux S; Eberle AN; Christe M; Sumanovski L; Heppeler A; Schmitt JS; Eisenwiener K; Beglinger C; Mäcke HR
Int J Cancer; 2002 Apr; 98(6):930-7. PubMed ID: 11948475
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Biological Evaluation of
Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
[TBL] [Abstract][Full Text] [Related]
14. Evaluation and comparison of a new DOTA and DTPA-bombesin agonist in vitro and in vivo in low and high GRPR expressing prostate and breast tumor models.
Pujatti PB; Foster JM; Finucane C; Hudson CD; Burnet JC; Pasqualoto KFM; Mengatti J; Mather SJ; de Araújo EB; Sosabowski JK
Appl Radiat Isot; 2015 Feb; 96():91-101. PubMed ID: 25479439
[TBL] [Abstract][Full Text] [Related]
15. In vivo imaging of human colorectal cancer using radiolabeled analogs of the uroguanylin peptide hormone.
Liu D; Overbey D; Watkinson LD; Daibes-Figueroa S; Hoffman TJ; Forte LR; Volkert WA; Giblin MF
Anticancer Res; 2009 Oct; 29(10):3777-83. PubMed ID: 19846908
[TBL] [Abstract][Full Text] [Related]
16. Selective targeting of E. coli heat-stable enterotoxin analogs to human colon cancer cells.
Giblin MF; Sieckman GL; Watkinson LD; Daibes-Figueroa S; Hoffman TJ; Forte LR; Volkert WA
Anticancer Res; 2006; 26(5A):3243-51. PubMed ID: 17094436
[TBL] [Abstract][Full Text] [Related]
17. Influence of chelate conjugation on a newly identified tumor-targeting peptide.
Mier W; Zitzmann S; Krämer S; Reed J; Knapp EM; Altmann A; Eisenhut M; Haberkorn U
J Nucl Med; 2007 Sep; 48(9):1545-52. PubMed ID: 17704241
[TBL] [Abstract][Full Text] [Related]
18. Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics.
Kumar P; Tripathi SK; Chen CP; Wickstrom E; Thakur ML
Mol Imaging Biol; 2019 Feb; 21(1):130-139. PubMed ID: 29802552
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of an
Kelly VJ; Wu ST; Gottumukkala V; Coelho R; Palmer K; Nair S; Erick T; Puri R; Ilovich O; Mukherjee P
Theranostics; 2020; 10(15):6946-6958. PubMed ID: 32550914
[No Abstract] [Full Text] [Related]
20. Primary Preclinical and Clinical Evaluation of
Li F; Zhang Z; Cai J; Chen X; Zhou Y; Ma X; Dong Q; Li F; Xi L
Clin Cancer Res; 2020 Mar; 26(6):1318-1326. PubMed ID: 31843751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
